Gynozol

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Gynozol

What is Gynozol? Quick Facts

Property Description
Active ingredient Miconazole Nitrate
Form Vaginal cream
Pharmacological class Azole antifungal (Imidazole derivative)
Common purpose Local anti-infective treatment
Origin Synthetic

What is Gynozol and What Type of Medicine is It?

Gynozol is a pharmaceutical preparation that serves as a local anti-infective treatment, primarily classified as an Azole antifungal agent. Its core identity is rooted in the single active ingredient, Miconazole Nitrate, which targets pathogenic fungi at the application site.

As a member of the imidazole derivative class, this medication has the capability to interfere with fungal organisms. Miconazole is a broad-spectrum antifungal agent effective against various species of fungi. This classification indicates that the drug is designed to provide focused anti-infective support, assisting the body in resolving local infections caused by susceptible fungal pathogens.

Composition, Origin, and Form of Gynozol

The medication is a synthetic product, meaning its active compound, Miconazole Nitrate, is chemically synthesized rather than being naturally sourced. Gynozol is specifically formulated as a vaginal cream, which is the precise dosage form designed for its localized therapeutic purpose, contrasting with formulations intended for systemic distribution. Miconazole is utilized in topical and vaginal formulations, characterized by established efficacy and safety profiles in these local applications.

This topical formulation is integral to the product's design, ensuring the active Miconazole Nitrate is delivered directly to the required area. The active ingredient is incorporated into an emollient cream base, providing a vehicle that allows for consistent application and coverage of the treatment surface, concentrating the therapeutic effect for local infections.

Regulatory References

  1. Miconazole Vaginal: MedlinePlus Drug Information
  2. Miconazole Nitrate Cream - DailyMed - NIH

What side effects are possible with Gynozol?

Possible side effects and safety information

The official safety profile for Miconazole Nitrate vaginal cream, as established by government regulatory documents, defines the possible adverse reactions by frequency and organ system.

Frequency-Classified Adverse Reactions

The majority of reported adverse events are Common and localized. These include application site reactions such as vaginal burning, itching, or local irritation. These local symptoms have been observed to occur more frequently at the initiation of treatment.

Less common reactions documented in official labeling may include headache, pelvic cramps, and rash. These effects are generally categorized within the Nervous System Disorders or Skin and Subcutaneous Tissue Disorders systems.

Serious Safety Considerations

The regulatory profile documents the potential for rare but serious adverse reactions, which often fall into the Not Known frequency category. These include severe hypersensitivity reactions such as anaphylaxis and angioedema (swelling of the face, lips, or throat).

Specific safety restrictions note that the medicine is contraindicated in individuals with known hypersensitivity to the active ingredient or other imidazole derivatives. A specific constraint documented in labeling relates to the potential for increased bleeding risk when this topical agent is used concurrently with oral anticoagulants (e.g., warfarin).

Population and Product Constraints

For pregnancy, regulatory text indicates that use during the first trimester is generally limited to situations where it is deemed necessary by a health professional. Furthermore, a specific safety constraint exists regarding the formulation base, which may damage latex products (e.g., condoms or diaphragms), potentially affecting their function.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documentation for Gynozol (Miconazole Nitrate Vaginal Cream) structures the overdose profile around two primary forms of exposure: excessive local application and accidental oral ingestion. Due to the product's design for minimal systemic absorption, the documented effects differ significantly between these scenarios.

Overuse of the cream locally may lead to documented localized skin irritation. Clinical manifestations associated with excessive topical application include redness, swelling, and a burning sensation at the site of use. Should these localized effects occur, official regulatory information suggests that temporarily discontinuing one or two applications and resuming the normal regimen may be sufficient.

The most critical regulatory guidance addresses accidental ingestion. Swallowing large quantities of the cream may result in stomach irritation. In this event, official labeling dictates that urgent medical attention is required.

Overdose Scenario Official Mandate
Excessive Topical Use No immediate action required
Accidental Oral Ingestion Seek immediate medical help or contact a Poison Control Center right away

It is officially stated that no specific antidote is known for Miconazole Nitrate overdose. All measures for accidental ingestion, which may include procedures like gastric lavage, are based on general appropriate supportive care as documented in the prescribing information.

Therapeutic Uses of Gynozol

Gynozol is primarily used to address the fungal infection associated with vulvovaginal candidiasis (vaginal yeast infection), which is generally caused by fungal organisms like Candida albicans. The active ingredient in Gynozol is commonly used for managing vaginal yeast infections, and may assist with easing symptoms related to inflammatory or irritative states, such as external vulvar itching and irritation.

The medication helps manage symptom clusters that may become intense or disruptive, including pruritus, burning, and noticeable local irritation. It is commonly used across conditions presenting with acute episodes and is considered relevant in situations involving recurrent or episodic manifestations. Providing symptomatic relief generally contributes to improved day-to-day comfort during periods when these symptoms are more noticeable.

“The supportive nature of the medication is relevant during phases of increased distress, and may help patients cope more steadily with symptom fluctuations.”

It supports patients during phases of increased distress or discomfort by addressing the escalation of symptoms, and assists with maintaining functional stability when symptoms interfere with routine activities.

Quick Fact: Managing Local Discomfort
Common Use: Used in situations involving certain distressing symptoms
Key Benefit: Contributes to easing the overall symptom load associated with the fungal infection.
Scenario: Relevant when short-term symptomatic assistance is needed during an episode.

Eligibility and Restrictions for Use

Gynozol (Miconazole Nitrate vaginal cream) is subject to specific regulatory eligibility criteria based on patient age, history, and concurrent health status, as defined by authoritative health agencies.

Contraindicated Populations

The product must not be used by individuals with a known hypersensitivity or history of allergic reaction to Miconazole or any component of the cream formulation.

Age-Related Eligibility

Use is established for adults and children 12 years of age and over. The medication is not for use in children under 12 years of age unless expressly directed by a healthcare provider.

Conditional Use and Restrictions

Mandatory consultation with a health professional is required in several circumstances:

Conditional Eligibility Factor Required Action
Pregnancy or Breastfeeding Must ask a health professional before use.
Taking Warfarin (blood thinner) Must ask a doctor or pharmacist before use.
Symptoms like fever, chills, abdominal pain, or foul-smelling discharge Must see a doctor (may indicate a serious condition).
Recurrent infections or presence of diabetes/HIV/AIDS Must see a doctor (may indicate an underlying condition).

What should I know about interactions with other medicines?

Interactions with other medicines and products

Gynozol (Butoconazole or Miconazole) has documented interactions with certain medicinal products and materials. The primary concern with this type of vaginal formulation relates to the non-medicinal ingredients in the cream base, as well as the drug's class-specific potential for systemic interaction.

Documented Interactions

Product Class / Substance Mechanism and Constraint
Latex or Rubber Products (Condoms, Diaphragms) The cream base contains mineral oil, which can physically weaken latex or rubber. This may cause barrier contraceptives to fail. These products should not be used for 72 hours (3 days) after treatment ends.
Oral Anticoagulants (e.g., Warfarin) Azole antifungals, such as Butoconazole and Miconazole, may inhibit liver enzymes (Cytochrome P450) responsible for metabolizing anticoagulants. Though systemic absorption from the vagina is minimal, this may increase the effect of the anticoagulant, leading to a risk of bleeding or bruising. Patients taking anticoagulants should consult a healthcare professional before use.
Other Vaginal Products (Tampons, Douches, Spermicides) Concurrent use is not recommended as it may affect the absorption or efficacy of the medication. Sanitary pads should be used instead of tampons during treatment.

Patients should provide a complete list of all medications, over-the-counter products, and supplements to their healthcare provider. This ensures a proper evaluation of potential interactions, particularly with high-risk medicines like anticoagulants, before initiating treatment.

Mechanism of Action

Targeting the Fungal Cell's Foundation: Ergosterol Biosynthesis

Gynozol's active component, Miconazole Nitrate, initiates its action by directly inhibiting the fungal enzyme 14alpha-demethylase. This enzyme is necessary for the Ergosterol biosynthesis pathway, a key process in synthesizing the fungal cell membrane's main structural component. This molecular interference halts the production of necessary membrane building blocks and causes the accumulation of toxic precursors, initiating a cascading physiological effect.

Structural Collapse and Fungicidal Action

The resulting deficit of Ergosterol and the incorporation of abnormal, toxic sterols severely compromise the structural integrity and function of the fungal cell membrane. This structural failure leads to the uncontrolled leakage of essential cellular contents, disrupting the pathogen's homeostasis. At sufficiently high local concentrations, this mechanism transitions from merely inhibiting growth (fungistatic) to causing irreversible damage and cell death (fungicidal), which is the resulting biological consequence of this mechanistic action.

Dosage and Administration Information

How Gynozol is Used: Administration Guidelines

Gynozol, a Miconazole Nitrate 2% vaginal cream, is administered via a dual-route protocol. The instructions define the precise route, dosage, duration, and contextual constraints for its application.


Administration Scope

Instruction Entity Description
Route of administration Intravaginal insertion and Topical/External application to the vulvar area.
Dosing schedule Intravaginal: One full applicatorful of the 2% cream (100 mg Miconazole Nitrate). Topical/External: A small amount of the cream applied to the fingertip.
Age-group rules The standard regimen is for adults and children 12 years of age and over. Use for children under 12 requires consultation with a doctor.
Missed-dose rules If a dose is missed, it should be used as soon as remembered; however, if it is almost time for the next scheduled dose, the missed dose is skipped. Dosing must not be doubled.

Use Patterns and Restrictions

Classification Detail
Intravaginal Course The full course requires a single applicatorful to be inserted once daily at bedtime for seven consecutive nights.
External Frequency The 2% cream is applied topically to the affected vulvar area two times daily for up to seven days as needed.
Use-Context Constraints The treatment protocol requires avoidance of tampons, douches, and spermicides, and avoidance of vaginal intercourse throughout the treatment period.

Connection to the Overall Use Protocol

The treatment protocol utilizes a standardized Dual Administration approach, separating the nightly intravaginal dosing from the twice-daily external application. This structure dictates precise time-of-day use and requires continuous treatment for seven days to complete the full regimen. Adherence to the stated use-context constraints, such as avoiding certain products, is integral to following the proper administration protocol.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Gynozol (Miconazole Nitrate)

The primary research for Gynozol's active ingredient, Miconazole Nitrate, was studied for Vulvovaginal Candidiasis (VVC), which is the clinical term for a vaginal yeast infection. The evidence base includes numerous Randomized Controlled Trials (RCTs) and subsequent meta-analyses that was evaluated in research settings for this condition. These studies are comparative trials designed to explore the outcomes of the drug versus an inactive substance (placebo) or other similar treatments.

Researchers in these studies examined two key measurements: the Microbiological outcome measure, which involves the confirmed assessment of Candida status, and the Clinical outcome measure, which tracks the measurement of local symptoms like itching and irritation. These outcomes was observed in groups of adult, non-pregnant females who had active VVC that was confirmed in a laboratory setting. Findings describe patterns observed in the studies, which contribute to understanding how patients reported their experience during short-term, acute episodes.


Types of Studies and Outcomes Measured

The evidence supporting Miconazole Nitrate is primarily derived from pivotal clinical evaluation trials and subsequent meta-analyses submitted to regulatory agencies. These studies often compare different topical azole formulations, and was evaluated in trials designed to evaluate research endpoints—meaning they examined similar levels of microbiological and clinical outcomes.

The main outcomes being tracked contribute to understanding how conditions with fluctuating or episodic manifestations changed over the observed time intervals. Specifically, studies monitored the proportion of patients reaching the defined symptom endpoint and tracked the time required for symptoms to subside. This research provides insight into short-term changes and documents patterns in the evidence landscape related to topical azole antifungals.


Long-Term Evidence and Recurrence Tracking

While the initial studies primarily focus on reaching a defined outcome shortly after treatment completion (typically assessed two to four weeks later), research also explores the issue of the infection returning, known as recurrence. Some studies and official analyses have monitored recurrence frequency over periods of up to three months following the defined treatment period.

However, the available data on long-term outcomes and the sustained prevention of recurrent episodes beyond a few months is limited across the majority of the original pivotal trials.

Key Studies & References

  1. Miconazole Nitrate Vaginal Suppository and Cream (Gynozol) U.S. FDA Approved Labeling
  2. Treatment of uncomplicated vulvovaginal candidiasis: topical or oral drugs? Single-day or multiple-day therapy? A network meta-analysis of randomized trials - PubMed, 2024

Frequently Asked Questions (FAQ)

Common questions about Gynozol (FAQ)


Q: Is Gynozol available over the counter?

According to official product information, Miconazole Nitrate 2% cream, the active ingredient in Gynozol, is often available as an Over-The-Counter (OTC) medication. This means it can be purchased without a prescription in many regions. However, the exact regulatory status can vary by country, and some higher-strength or combination formulations may still require a prescription.


Q: Can Gynozol affect birth control pills?

Official regulatory documents indicate that Miconazole Nitrate vaginal cream is generally not described as directly reducing the effectiveness of oral birth control pills. However, a specific warning is associated with the cream's base ingredients. These ingredients may physically weaken latex or rubber products, and official guidance advises against relying on barrier contraceptives like condoms and diaphragms during or shortly after treatment.


Q: Does Gynozol interact with alcohol?

Official warnings for the topical Miconazole Nitrate vaginal cream do not typically include a direct warning against consuming alcohol. This is in contrast to some oral antifungal medications or combination products that contain Miconazole. Therefore, official guidance recommends reviewing the specific product labeling they receive for guidance on alcohol use.


Q: Are there any long-term side effects noted with Gynozol use?

Regulatory safety data primarily focuses on short-term use and the known common side effects that occur during treatment, such as localized irritation. Official drug labeling documents do not typically contain information regarding side effects or safety implications resulting from long-term or chronic use.


Q: Is Gynozol suitable for people with a history of liver problems?

Studies show that Miconazole can affect certain liver enzymes (known as CYP450) when absorbed systemically. Because the absorption of the vaginal cream is minimal, the possibility of clinically relevant effects on the liver is typically minimal. Nonetheless, official information indicates the need for caution, especially if the user is taking other medications that are metabolized by the liver.


Q: Can using Gynozol affect a period or menstrual cycle?

Official regulatory guidelines describe the treatment course as needing completion even if the menstrual period begins. The medication is not described in official documents as having an effect on the timing, duration, or flow of the menstrual cycle itself. The protocol involves using sanitary pads instead of tampons during treatment.


Q: What is the difference between the cream and the tablet version of Gynozol?

Miconazole Nitrate, the active ingredient, is available in multiple delivery vehicles, primarily as a 2% vaginal cream and as vaginal suppositories (often called vaginal tablets). The core difference lies in the formulation and the resulting administration protocol, which can vary in the number of consecutive days required for treatment.


Q: Does Gynozol expire, and how long is its shelf life?

Yes, Gynozol has a defined shelf life, which is typically noted on the packaging and the tube itself. Official regulations require that the product not be used after this expiration date to ensure the stability and quality of the active ingredient. The product is required to be stored as instructed to maintain its integrity until the expiration date.


Q: Can Gynozol be used while breastfeeding, according to regulatory documents?

Regulatory documents state that it is not definitively known if Miconazole is transferred into human milk during use. Because the vaginal cream is minimally absorbed into the bloodstream, the possibility of significant risk to a nursing infant is viewed as minimal. However, due to this uncertainty, official information indicates that caution is appropriate when the product is used while breastfeeding.


Q: Does Gynozol have any known effects on laboratory blood tests?

Official information is not routinely shown to affect general laboratory blood test results. The most relevant information is that Miconazole can interact with certain oral blood-thinning medicines (anticoagulants) by affecting the liver enzymes that process them. This interaction can potentially change the blood test values used to monitor those specific anticoagulant medicines.


Q: Are there different strengths of Gynozol available?

The active ingredient Miconazole Nitrate is manufactured in several different strengths and formats for use against vaginal yeast infections. Common formats include the 2% cream, lower-dose suppositories often used for seven days, and higher-dose suppositories sometimes used for shorter treatment periods.


Q: Is Gynozol described as an anti-inflammatory drug?

Gynozol’s active ingredient is categorized primarily as an Azole antifungal medication. The mechanism of action involves targeting and inhibiting the growth of fungus. The approved regulatory labeling does not include a description of the medication as an anti-inflammatory drug.


Q: Is Gynozol available as a generic medicine?

Yes, the active component of Gynozol, Miconazole Nitrate, is widely available as a generic medicine. Following patent expiration, generic versions of the vaginal cream and other formulations are marketed under various brand names and as unbranded products.


Q: Can people with diabetes use Gynozol?

Official drug labeling often includes a general caution regarding individuals with certain underlying health conditions. This advisory relates to individuals with diabetes or those who have recurrent yeast infections due to underlying health issues.


Q: Why do some people experience stomach upset when using Gynozol?

While systemic side effects are minimal with this topical application, official regulatory documents list abdominal cramping and, in rare cases, nausea, among the possible less common adverse reactions. These symptoms are thought to be related to the minimal amount of the drug that is absorbed into the bloodstream.


Q: Does Gynozol affect energy levels?

General fatigue or changes in energy levels are not commonly listed in the safety profile for Miconazole Nitrate vaginal cream. However, official regulatory labels for the active ingredient, based on clinical trial data, have occasionally noted fatigue as a reported adverse event by a small percentage of users.


Q: Can Gynozol be used for prevention, according to regulatory sources?

The approved regulatory indication for Gynozol is the local treatment of vulvovaginal candidiasis (yeast infection). Official regulatory documentation is not described as including its use as a routine or long-term preventative measure.

How should Gynozol be stored and disposed of?

How to Store and Dispose of Gynozol?

The storage and disposal of Gynozol (Miconazole Nitrate vaginal cream) must follow official regulatory requirements to ensure product stability and safety. The medication is required to be stored at Controlled Room Temperature, specifically between 20 C and 25 C. It is mandatory to protect the cream from freezing and from exposure to excess heat, moisture, and direct light, requiring it to be kept in its original, tightly closed container.

Key Storage and Disposal Rules

Requirement Type Official Instruction
Temperature Restriction Must be stored at 20 C to 25 C; Do not freeze.
Child Safety Keep out of the sight and reach of children.
Disposal Do not flush down a toilet or pour down a drain. Unused cream should be prepared for household trash disposal by mixing it with an unappealing substance.

These mandated conditions preserve the medication's intended stability up to its expiration date.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Gynozol found in:

A-Z Index: